1. P1278: ACTIVATION OF THE NECROPTOSIS PATHWAY PLAYS A ROLE IN SYNERGISM WITH COMBINATION OF THE IAP ANTAGONIST, TOLINAPANT AND HYPOMETHYLATING AGENTS (HMA) IN IN VITRO MODELS OF T-CELL LYMPHOMA (TCL). (23rd June 2022) Authors: Manavalan, J. S.; Pal, I.; Pursley, A.; Ward, G.; Smyth, T.; Sims, M.; Feith, D.; Loughran, T. P.; O'Connor, O. A.; Marchi, E. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1163 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S217: PRELIMINARY ANALYSIS OF THE PHASE II STUDY USING TOLINAPANT (ASTX660) MONOTHERAPY IN 98 PERIPHERAL T-CELL LYMPHOMA AND 51 CUTANEOUS T-CELL LYMPHOMA SUBJECTS WITH RELAPSED REFRACTORY DISEASE. (23rd June 2022) Authors: Michot, J.-M.; Mehta, A.; Samaniego, F.; Bachy, E.; Zinzani, P. L.; Prica, A.; Colins, G. P.; Ribrag, V; Wagner-Johnston, N.; El-Sharkawi, D.; O'Connor, O. A.; Wilcox, R.; Wang, L.; Wilson, L.; Sims, M.; Taylor, J. A.; Keer, H. N.; Foss, F. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗